Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Baxter
Chinese Patent Office
Julphar
Johnson and Johnson
US Department of Justice

Generated: April 25, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021337

« Back to Dashboard

NDA 021337 describes INVANZ, which is a drug marketed by Merck Sharp Dohme and is included in one NDA. It is available from two suppliers. Additional details are available on the INVANZ profile page.

The generic ingredient in INVANZ is ertapenem sodium. There are eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the ertapenem sodium profile page.
Summary for 021337
Tradename:INVANZ
Applicant:Merck Sharp Dohme
Ingredient:ertapenem sodium
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 021337
Suppliers and Packaging for NDA: 021337
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
INVANZ ertapenem sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 021337 NDA Merck Sharp & Dohme Corp. 0006-3843 0006-3843-71 10 VIAL, SINGLE-DOSE in 1 TRAY (0006-3843-71) > 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSE
INVANZ ertapenem sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 021337 NDA Par Pharmaceutical Inc. 42023-221 42023-221-85 10 VIAL, SINGLE-DOSE in 1 TRAY (42023-221-85) > 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSE (42023-221-89)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INTRAMUSCULAR, INTRAVENOUSStrengthEQ 1GM BASE/VIAL
Approval Date:Nov 21, 2001TE:APRLD:Yes

Expired US Patents for NDA 021337

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme INVANZ ertapenem sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 021337-001 Nov 21, 2001 ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme INVANZ ertapenem sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 021337-001 Nov 21, 2001 ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme INVANZ ertapenem sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 021337-001 Nov 21, 2001 ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme INVANZ ertapenem sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 021337-001 Nov 21, 2001 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
UBS
Colorcon
Cipla
Federal Trade Commission
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.